Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection.
Snydman
David R
DR
Division of Geographic Medicine and Infectious Disease, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA. dsnydman@tuftsmedicalcenter.org
D000465:Algorithms; D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D024882:Drug Resistance, Viral; D015774:Ganciclovir / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D000077339:Leflunomide; D012263:Ribonucleosides / Q000627:therapeutic use; D033581:Stem Cell Transplantation / Q000009:adverse effects; D014181:Transplantation Immunology; D004004:Dichlororibofuranosylbenzimidazole / Q000031:analogs & derivatives
D000998:Antiviral Agents; D001562:Benzimidazoles; D015774:Ganciclovir; D007555:Isoxazoles; D000077339:Leflunomide; D012263:Ribonucleosides; C400401:maribavir; D004004:Dichlororibofuranosylbenzimidazole